Terrence O. Moore Retires as Chief
Commercial Officer
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical
company focused on the development and commercialization of
innovative medicines to address unmet medical needs in central
nervous system (CNS) disorders, today announced Michael J. Yang has
joined ACADIA as Executive Vice President and Chief Commercial
Officer. Mr. Yang succeeds Terrence O. Moore, who has served as
ACADIA’s Chief Commercial Officer since 2013, and is now
retiring.
This Smart News Release features multimedia.
View the full release here:
http://www.businesswire.com/news/home/20170330005419/en/
Michael J. Yang, Executive Vice
President, Chief Commercial Officer (Photo: Business Wire)
“I am delighted to welcome Michael to our team,” said Steve
Davis, ACADIA’s President and Chief Executive Officer. “Michael is
a seasoned executive with extensive expertise in successfully
launching and growing major pharmaceutical products across a number
of therapeutic areas, including CNS. His patient-centric approach,
proven leadership skills, and focus on innovation will be of great
value to the ongoing commercialization of NUPLAZID in Parkinson’s
disease psychosis and its potential expansion into other areas of
large unmet need.”
“Central nervous system disorders are one of the biggest
challenges to our healthcare system and severely impact the lives
of both patients and their families,” said Michael Yang. “As an
innovative, first-in-class product, NUPLAZID is transforming the
treatment of patients suffering from Parkinson’s disease psychosis.
I look forward to building on the success of NUPLAZID.”
“We thank Terry Moore for his significant contributions to
ACADIA over the past four years,” added Mr. Davis. “Under his
leadership, we have laid a strong foundation for the continued
growth of NUPLAZID. We wish him well in his retirement as he plans
to move back to the East Coast and spend more time with his
family.”
Mr. Moore commented, “I am proud of what we have been able to
achieve – building the commercial foundation, launching NUPLAZID,
and bringing this novel drug to patients in need. After more than
30 years in the life sciences industry, I’m pleased to hand the
reins over to Michael to lead the next phase of growth for ACADIA,
and I look forward to watching the company reach new levels of
success.”
Mr. Yang joins ACADIA from Janssen Pharmaceutical Companies of
Johnson & Johnson, where he served as President of Janssen
Biotech Inc. and was responsible for building Janssen's U.S.
Immunology business, generating more than $8 billion in annual
revenues. Mr. Yang began his career at Johnson & Johnson in
1997 and held numerous senior commercial positions such as
President, CNS where he was responsible for growing the
anti-psychotic long-acting therapy portfolio. His broad background
of commercialization and general management experience also
includes roles as the Worldwide General Manager of the Medical
Device companies of Therakos, Inc and Veridex, LLC, where he
launched new platforms, expanded global revenues and diversified
the product lines. Prior to that, Mr. Yang was Vice President of
Sales and Marketing, Oncology at Ortho Biotech Inc.
Mr. Yang earned his Bachelor of Science degree in Business
Administration, Marketing from San Diego State University. Mr. Yang
will serve as a member of ACADIA’s executive team and report to Mr.
Davis, effective today.
About NUPLAZID® (pimavanserin)
NUPLAZID is the first and only FDA-approved treatment for
hallucinations and delusions associated with Parkinson’s disease
(PD) psychosis. NUPLAZID is a non-dopaminergic, selective serotonin
inverse agonist preferentially targeting 5-HT2A receptors that are
thought to play an important role in PD Psychosis. NUPLAZID is an
oral medicine taken once a day with a recommended dose of 34 mg
(two 17-mg tablets). ACADIA discovered this new chemical entity and
holds worldwide rights to develop and commercialize NUPLAZID.
About ACADIA Pharmaceuticals
ACADIA is a biopharmaceutical company focused on the development
and commercialization of innovative medicines to address unmet
medical needs in central nervous system disorders. ACADIA maintains
a website at www.acadia-pharm.com to which we regularly post copies
of our press releases as well as additional information and through
which interested parties can subscribe to receive e-mail
alerts.
Forward-Looking Statements
Statements in this press release that are not strictly
historical in nature are forward-looking statements. These
statements include but are not limited to statements related to the
benefits to be derived from NUPLAZID (pimavanserin); the utility or
expansion of pimavanserin in indications other than hallucinations
and delusions associated with PD Psychosis; and any future growth
or success of NUPLAZID or ACADIA. These statements are only
predictions based on current information and expectations and
involve a number of risks and uncertainties. Actual events or
results may differ materially from those projected in any of such
statements due to various factors, including the risks and
uncertainties inherent in drug discovery, development, and
commercialization, and the fact that past results of clinical
trials may not be indicative of future trial results. For a
discussion of these and other factors, please refer to ACADIA’s
annual report on Form 10-K for the year ended December 31, 2016 as
well as ACADIA’s subsequent filings with the Securities and
Exchange Commission. You are cautioned not to place undue reliance
on these forward-looking statements, which speak only as of the
date hereof. This caution is made under the safe harbor provisions
of the Private Securities Litigation Reform Act of 1995. All
forward-looking statements are qualified in their entirety by this
cautionary statement and ACADIA undertakes no obligation to revise
or update this press release to reflect events or circumstances
after the date hereof, except as required by law.
Important Safety Information and
Indication for NUPLAZID (pimavanserin) tablets
WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH
DEMENTIA-RELATED PSYCHOSISElderly patients with
dementia-related psychosis treated with antipsychotic drugs are at
an increased risk of death. NUPLAZID is not approved for the
treatment of patients with dementia-related psychosis unrelated to
the hallucinations and delusions associated with Parkinson’s
disease psychosis.
NUPLAZID is an atypical antipsychotic indicated for the
treatment of hallucinations and delusions associated with
Parkinson’s disease psychosis.
QT Interval Prolongation: NUPLAZID prolongs the QT interval. The
use of NUPLAZID should be avoided in patients with known QT
prolongation or in combination with other drugs known to prolong QT
interval including Class 1A antiarrhythmics or Class 3
antiarrhythmics, certain antipsychotic medications, and certain
antibiotics. NUPLAZID should also be avoided in patients with a
history of cardiac arrhythmias, as well as other circumstances that
may increase the risk of the occurrence of torsade de pointes
and/or sudden death, including symptomatic bradycardia, hypokalemia
or hypomagnesemia, and presence of congenital prolongation of the
QT interval.
Adverse Reactions: The most common adverse reactions (≥2% for
NUPLAZID and greater than placebo) were peripheral edema (7% vs
2%), nausea (7% vs 4%), confusional state (6% vs 3%), hallucination
(5% vs 3%), constipation (4% vs 3%), and gait disturbance (2% vs
<1%).
Drug Interactions: Strong CYP3A4 inhibitors (eg, ketoconazole)
increase NUPLAZID concentrations. Reduce the NUPLAZID dose by
one-half. Strong CYP3A4 inducers may reduce NUPLAZID exposure,
monitor for reduced efficacy. Increase in NUPLAZID dosage may be
needed.
Renal Impairment: No dosage adjustment for NUPLAZID is needed in
patients with mild to moderate renal impairment. Use of NUPLAZID is
not recommended in patients with severe renal impairment.
Hepatic Impairment: Use of NUPLAZID is not recommended in
patients with hepatic impairment. NUPLAZID has not been evaluated
in this patient population.
Pregnancy: Use of NUPLAZID in pregnant women has not been
evaluated and should therefore be used in pregnancy only if the
potential benefit justifies the potential risk to the mother and
fetus.
Pediatric Use: Safety and efficacy have not been established in
pediatric patients.
Dosage and Administration: Recommended dose: 34 mg per day,
taken orally as two 17-mg tablets once daily, without
titration.
For additional Important Safety Information, including boxed
warning, please see the full Prescribing Information for NUPLAZID
at
https://www.nuplazid.com/pdf/NUPLAZID_Prescribing_Information.pdf.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170330005419/en/
Investor Contact:ACADIA Pharmaceuticals Inc.Lisa Barthelemy(858)
558-2871ir@acadia-pharm.comorMedia Contact:Taft CommunicationsBob
Laverty(609) 558-5570bob@taftcommunications.com
Acadia Pharmaceuticals (NASDAQ:ACAD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Acadia Pharmaceuticals (NASDAQ:ACAD)
Historical Stock Chart
From Apr 2023 to Apr 2024